This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| SARS | 7251 |
| COVID-19 | 4441 |
| CoV-2 | 3783 |
| Coronavirus | 2465 |
| CoV | 2234 |
| MERS | 1683 |
| el | 1625 |
| China | 1448 |
| RNA | 1062 |
| los | 954 |
| Wuhan | 799 |
| East | 711 |
| con | 697 |
| Middle | 669 |
| ACE2 | 668 |
| para | 620 |
| S | 611 |
| Disease | 606 |
| un | 605 |
| del | 580 |
| Syndrome | 499 |
| CoVs | 465 |
| Novel | 451 |
| las | 450 |
| Respiratory | 448 |
| Health | 445 |
| pacientes | 431 |
| una | 422 |
| en | 402 |
| PCR | 391 |
| CT | 338 |
| United | 328 |
| India | 326 |
| RT | 313 |
| como | 303 |
| T | 295 |
| por | 288 |
| Se | 280 |
| States | 261 |
| Clinical | 254 |
| World | 247 |
| es | 237 |
| March | 227 |
| M | 226 |
| Virus | 225 |
| Italy | 224 |
| La | 222 |
| uso | 215 |
| RBD | 210 |
| ICU | 208 |
| IFN | 207 |
| April | 205 |
| HCoV | 202 |
| N | 194 |
| recomienda | 191 |
| January | 190 |
| New | 189 |
| Human | 188 |
| ARDS | 184 |
| • | 182 |
| Protein | 182 |
| Coronaviruses | 176 |
| su | 175 |
| C | 175 |
| Organization | 171 |
| Treatment | 169 |
| WHO | 165 |
| Ebola | 163 |
| US | 161 |
| Remdesivir | 158 |
| Fig | 153 |
| remdesivir | 150 |
| Pneumonia | 150 |
| Table | 149 |
| Saudi | 149 |
| Arabia | 149 |
| Analysis | 149 |
| ventilación | 147 |
| puede | 147 |
| TMPRSS2 | 146 |
| South | 145 |
| Korea | 144 |
| Patients | 142 |
| Infection | 142 |
| Pandemic | 141 |
| J | 140 |
| ser | 138 |
| II | 138 |
| CoV-1 | 137 |
| May | 136 |
| IL-6 | 136 |
| February | 136 |
| A | 136 |
| Covid-19 | 134 |
| der | 133 |
| FDA | 129 |
| paciente | 128 |
| CD4 | 127 |
| NL63 | 126 |
| ritonavir | 125 |
| IgM | 125 |
| HCQ | 124 |
| lo | 123 |
| Review | 122 |
| December | 122 |
| Study | 121 |
| enfermedad | 121 |
| Transmission | 121 |
| OC43 | 120 |
| USA | 118 |
| IgG | 118 |
| S1 | 117 |
| diagnóstico | 116 |
| Trump | 116 |
| National | 116 |
| Control | 116 |
| Spike | 115 |
| Europe | 115 |
| AMCI | 115 |
| tratamiento | 114 |
| sha | 114 |
| El | 114 |
| CDC | 114 |
| Germany | 112 |
| Prevention | 112 |
| riesgo | 111 |
| más | 111 |
| estudios | 111 |
| estudio | 111 |
| UCI | 111 |
| Hydroxychloroquine | 111 |
| UK | 110 |
| Hong | 110 |
| HIV | 110 |
| se | 107 |
| mortalidad | 107 |
| debe | 107 |
| Viral | 107 |
| Kong | 107 |
| Report | 106 |
| CD8 | 105 |
| Care | 104 |
| DOI | 102 |
| días | 99 |
| Japan | 99 |
| mg | 98 |
| manejo | 98 |
| University | 98 |
| CoV. | 98 |
| α | 97 |
| Development | 97 |
| E | 95 |
| Society | 95 |
| Structure | 94 |
| Research | 94 |
| lopinavir | 93 |
| Influenza | 93 |
| entre | 92 |
| Detection | 92 |
| Africa | 91 |
| SDRA | 91 |
| han | 91 |
| International | 90 |
| Hubei | 88 |
| sobre | 87 |
| Chinese | 87 |
| mecánica | 86 |
| MHV | 86 |
| Emergency | 86 |
| TNF | 85 |
| Coronaviridae | 85 |
| sospecha | 85 |
| casos | 85 |
| Replication | 84 |
| PPE | 84 |
| Association | 84 |
| esta | 83 |
| B | 82 |
| Los | 82 |
| Chloroquine | 81 |
| Case | 81 |
| mayor | 80 |
| York | 80 |
| Use | 80 |
| Medicine | 79 |
| IBV | 79 |
| von | 78 |
| pueden | 78 |
| Global | 78 |
| este | 76 |
| alta | 76 |
| Wang | 76 |
| Group | 75 |
| France | 75 |
| America | 75 |
| Public | 75 |
| pulmonar | 75 |
| Spain | 74 |
| HKU1 | 74 |
| Characteristics | 74 |
| intubación | 73 |
| día | 73 |
| RdRp | 73 |
| Figure | 73 |
| TGEV | 72 |
| respiratoria | 72 |
| le | 72 |
| infección | 71 |
| grupo | 71 |
| Chest | 71 |
| BCV | 70 |
| Hospital | 70 |
| Center | 70 |
| cuidados | 70 |
| Molecular | 70 |
| des | 70 |
| Risk | 70 |
| eine | 69 |
| COVID | 69 |
| du | 69 |
| azithromycin | 68 |
| S2 | 68 |
| Medical | 68 |
| Lopinavir | 68 |
| personal | 67 |
| fue | 66 |
| Infectious | 66 |
| presión | 65 |
| clínico | 65 |
| N95 | 65 |
| Diseases | 64 |
| Betacoronavirus | 64 |
| European | 64 |
| Management | 64 |
| tiempo | 63 |
| meta | 63 |
| Corona | 63 |
| Cell | 63 |
| síntomas | 62 |
| evidencia | 62 |
| Singapore | 62 |
| ORF | 62 |
| I | 62 |
| CQ | 62 |
| Antibody | 62 |
| H1N1 | 61 |
| Drug | 61 |
| HIV-1 | 61 |
| hydroxychloroquine | 60 |
| Lancet | 60 |
| ER | 60 |
| CRISPR | 60 |
| mRNA | 60 |
| Province | 59 |
| Kingdom | 59 |
| NK | 59 |
| lymphopenia | 59 |
| clínica | 59 |
| ont | 59 |
| son | 59 |
| American | 58 |
| BCoV | 58 |
| DC | 58 |
| Receptor | 58 |
| Science | 58 |
| coronavirus | 58 |
| hasta | 58 |
| menor | 58 |
| salud | 58 |
| IC | 57 |
| First | 57 |
| DPP4 | 57 |
| COV-2 | 57 |
| Asia | 57 |
| June | 56 |
| ELISA | 56 |
| CNS | 56 |
| President | 55 |
| Diagnosis | 55 |
| HE | 55 |
| Host | 55 |
| College | 55 |
| Trial | 55 |
| si | 55 |
| soporte | 55 |
| horas | 55 |
| mit | 54 |
| bei | 54 |
| Ritonavir | 54 |
| Las | 54 |
| July | 54 |
| Institute | 54 |
| Identification | 54 |
| HCoVs | 54 |
| Committee | 54 |
| Zika | 53 |
| City | 53 |
| System | 53 |
| Pathogenesis | 53 |
| bajo | 53 |
| zu | 53 |
| pero | 53 |
| fueron | 53 |
| Impact | 52 |
| Associated | 52 |
| Convalescent | 52 |
| Data | 52 |
| Evaluation | 52 |
| HCoV-229E | 52 |
| Immune | 52 |
| Iran | 52 |
| Response | 52 |
| Severe | 52 |
| cuenta | 52 |
| einer | 52 |
| pandemia | 52 |
| protección | 52 |
| Hepatitis | 51 |
| AI | 51 |
| FIP | 51 |
| Li | 51 |
| Outbreak | 51 |
| alto | 51 |
| cols | 51 |
| realizar | 51 |
| Guangdong | 50 |
| CFR | 50 |
| COVID19 | 50 |
| Discovery | 50 |
| DNA | 50 |
| L | 50 |
| Vaccine | 50 |
| Vero | 50 |
| contra | 50 |
| sera | 49 |
| respiratorio | 49 |
| nivel | 49 |
| U.S. | 49 |
| Map | 49 |
| Infections | 49 |
| Angiotensin | 48 |
| Republic | 48 |
| Rapid | 48 |
| dosis | 47 |
| deben | 47 |
| atención | 47 |
| Safety | 47 |
| Plasma | 47 |
| Nucleocapsid | 47 |
| General | 47 |
| Favipiravir | 47 |
| En | 47 |
| EU | 47 |
| Canada | 47 |
| Acute | 47 |
| Findings | 46 |
| Genome | 46 |
| Zhang | 46 |
| ADE | 46 |
| Guidelines | 46 |
| cual | 46 |
| aguda | 46 |
| severa | 46 |
| inicio | 46 |
| clínicos | 46 |
| Ill | 45 |
| Antiviral | 45 |
| Chen | 45 |
| D | 45 |
| De | 45 |
| PLpro | 45 |
| Zhou | 45 |
| compromiso | 45 |
| otros | 45 |
| oxigenación | 45 |
| été | 45 |
| Patient | 44 |
| HKU15 | 44 |
| Outcomes | 44 |
| PEDV | 44 |
| intensivos | 44 |
| Therapy | 44 |
| oxígeno | 44 |
| ® | 44 |
| β | 44 |
| críticos | 43 |
| Bat | 43 |
| Golgi | 43 |
| Guidance | 43 |
| Les | 43 |
| cuales | 43 |
| dans | 43 |
| mejoría | 43 |
| niveles | 43 |
| nucleocapsid | 43 |
| hepatitis | 42 |
| III | 42 |
| North | 42 |
| terapia | 42 |
| resultados | 42 |
| vía | 42 |
| sido | 42 |
| Journal | 41 |
| ACE-2 | 41 |
| Children | 41 |
| Complex | 41 |
| Department | 41 |
| Hospitalized | 41 |
| Minister | 41 |
| Origin | 41 |
| les | 41 |
| número | 41 |
| γ | 41 |
| Wu | 40 |
| Benjamin | 40 |
| G | 40 |
| HCV | 40 |
| State | 40 |
| tipo | 40 |
| auf | 40 |
| severo | 40 |
| tiene | 40 |
| todos | 40 |
| und | 40 |
| Arbidol | 39 |
| Commission | 39 |
| ORF1a | 39 |
| Distress | 39 |
| Emerging | 39 |
| Epidemiology | 39 |
| Interferon | 39 |
| Liu | 39 |
| seguridad | 39 |
| Tocilizumab | 39 |
| donde | 39 |
| ingreso | 39 |
| neumonía | 39 |
| pronóstico | 39 |
| werden | 39 |
| ya | 39 |
| cas | 39 |
| Network | 38 |
| CoV2 | 38 |
| Early | 38 |
| IV | 38 |
| LAMP | 38 |
| Nrf-2 | 38 |
| desde | 38 |
| durante | 38 |
| estos | 38 |
| menos | 38 |
| recursos | 38 |
| utilizar | 38 |
| Membrane | 37 |
| Administration | 37 |
| CSF | 37 |
| Efficacy | 37 |
| Food | 37 |
| LPV | 37 |
| Lockdown | 37 |
| Lung | 37 |
| MS | 37 |
| manera | 37 |
| Supplementary | 37 |
| convaleciente | 37 |
| decisiones | 37 |
| dos | 37 |
| estrategia | 37 |
| falla | 37 |
| realización | 37 |
| recibieron | 37 |
| Ministry | 36 |
| Adults | 36 |
| Animal | 36 |
| Autophagy | 36 |
| Effect | 36 |
| Intensive | 36 |
| Interim | 36 |
| momento | 36 |
| NMD | 36 |
| así | 36 |
| baja | 36 |
| coronaviruses | 36 |
| crítico | 36 |
| cuando | 36 |
| Por | 36 |
| Phase | 35 |
| Cov-2 | 35 |
| EPP | 35 |
| Features | 35 |
| IRF3 | 35 |
| Imaging | 35 |
| KSA | 35 |
| Prime | 35 |
| equipo | 35 |
| flujo | 35 |
| hipoxemia | 35 |
| medidas | 35 |
| nan | 35 |
| sugiere | 35 |
| Assessment | 34 |
| IL-10 | 34 |
| Brazil | 34 |
| EM | 34 |
| England | 34 |
| Entry | 34 |
| Factors | 34 |
| Function | 34 |
| HLA | 34 |
| posición | 34 |
| Le | 34 |
| Thailand | 34 |
| Times | 34 |
| Viruses | 34 |
| condiciones | 34 |
| das | 34 |
| vida | 34 |
| Taiwan | 34 |
| considerar | 33 |
| ECMO | 33 |
| Russia | 33 |
| Time | 33 |
| diferentes | 33 |
| recomendaciones | 33 |
| severidad | 33 |
| sin | 33 |
| Social | 32 |
| COVID-2019 | 32 |
| Centre | 32 |
| Critical | 32 |
| Delhi | 32 |
| November | 32 |
| Protease | 32 |
| endosomal | 32 |
| TCZ | 32 |
| necesario | 32 |
| qPCR | 32 |
| reducción | 32 |
| tocilizumab | 32 |
| criterios | 32 |
| Es | 31 |
| Nonstructural | 31 |
| Nidovirales | 31 |
| MHC | 31 |
| Laboratory | 31 |
| Cross | 31 |
| E6 | 31 |
| Donald | 31 |
| Alphacoronavirus | 31 |
| Pathway | 31 |
| ORF8 | 31 |
| utilización | 31 |
| Rhinolophus | 31 |
| luego | 31 |
| auch | 31 |
| procedimiento | 31 |
| medRxiv | 31 |
| traslado | 31 |
| lesión | 31 |
| infecciones | 31 |
| efectos | 31 |
| disponibilidad | 31 |
| Regulations | 30 |
| Application | 30 |
| C. | 30 |
| CC | 30 |
| Cancer | 30 |
| Gene | 30 |
| Open | 30 |
| Pediatric | 30 |
| SSEs | 30 |
| Si | 30 |
| Structural | 30 |
| Vietnam | 30 |
| estándar | 30 |
| mAbs | 30 |
| recomendación | 30 |
| sea | 30 |
| tanto | 30 |
| Interaction | 29 |
| Testing | 29 |
| Studies | 29 |
| Randomized | 29 |
| Protection | 29 |
| PEEP | 29 |
| Beijing | 29 |
| Government | 29 |
| Community | 29 |
| ChAdOx1 | 29 |
| bronchoalveolar | 29 |
| Azithromycin | 29 |
| Antibodies | 29 |
| aerosoles | 29 |
| TCoV | 29 |
| clínicas | 29 |
| ou | 29 |
| también | 29 |
| complicaciones | 29 |
| sont | 29 |
| solo | 29 |
| respuesta | 29 |
| pp1ab | 29 |
| síndrome | 29 |
| médico | 29 |
| ivermectin | 29 |
| hospitalaria | 29 |
| ensayos | 29 |
| consentimiento | 29 |
| médica | 29 |
| Oxford | 28 |
| Una | 28 |
| Team | 28 |
| Security | 28 |
| Recommendations | 28 |
| Proteins | 28 |
| Huanan | 28 |
| ORF1b | 28 |
| Inhibitors | 28 |
| HR1 | 28 |
| Epidemic | 28 |
| Centers | 28 |
| algunos | 28 |
| Union | 28 |
| Cases | 28 |
| aérea | 28 |
| multicentre | 28 |
| cada | 28 |
| à | 28 |
| según | 28 |
| revisión | 28 |
| plasma | 28 |
| oder | 28 |
| través | 28 |
| importante | 28 |
| evaluar | 28 |
| disminución | 28 |
| decisión | 28 |
| control | 28 |
| favipiravir | 28 |
| FUNDAMENTO | 27 |
| IL-8 | 27 |
| Huang | 27 |
| Genomic | 27 |
| GM | 27 |
| Comparative | 27 |
| DCs | 27 |
| Cryo | 27 |
| CI | 27 |
| Australia | 27 |
| Mechanisms | 27 |
| Inhibition | 27 |
| Polymerase | 27 |
| información | 27 |
| viral | 27 |
| Systematic | 27 |
| TCM | 27 |
| Taxonomy | 27 |
| asociada | 27 |
| elevación | 27 |
| evitar | 27 |
| pH | 27 |
| sus | 27 |
| September | 27 |
| D. | 26 |
| Director | 26 |
| Kawasaki | 26 |
| Dynamics | 26 |
| Baricitinib | 26 |
| Cells | 26 |
| ACE | 26 |
| Bank | 26 |
| Al | 26 |
| Activity | 26 |
| Activation | 26 |
| 3CL | 26 |
| Incubation | 26 |
| medicamentos | 26 |
| NHS | 26 |
| debido | 26 |
| People | 26 |
| volumen | 26 |
| está | 26 |
| disminuir | 26 |
| tener | 26 |
| chez | 26 |
| ces | 26 |
| apoyo | 26 |
| análisis | 26 |
| Sciences | 26 |
| Family | 25 |
| PRCV | 25 |
| Microbiology | 25 |
| Meta | 25 |
| Med | 25 |
| Lombardy | 25 |
| H7N9 | 25 |
| H5N1 | 25 |
| Air | 25 |
| FIPV | 25 |
| Effectiveness | 25 |
| Dr. | 25 |
| Dependent | 25 |
| BBC | 25 |
| Aerosol | 25 |
| PubMed | 25 |
| Potential | 25 |
| F | 25 |
| Spread | 25 |
| kg | 25 |
| vivo | 25 |
| Veterinary | 25 |
| trabajo | 25 |
| tomar | 25 |
| teniendo | 25 |
| servicios | 25 |
| sensibilidad | 25 |
| parte | 25 |
| IgA | 25 |
| ist | 25 |
| efecto | 25 |
| durch | 25 |
| Y | 25 |
| chloroquine | 25 |
| aumento | 25 |
| antes | 25 |
| J. | 24 |
| S. | 24 |
| Ribavirin | 24 |
| RR | 24 |
| PaO2 | 24 |
| Mouse | 24 |
| Humans | 24 |
| Isolation | 24 |
| IGIV | 24 |
| West | 24 |
| Cardiovascular | 24 |
| Appendix | 24 |
| Tanzania | 24 |
| PND | 24 |
| Yang | 24 |
| d'une | 24 |
| uno | 24 |
| tienen | 24 |
| punto | 24 |
| intensivo | 24 |
| hallazgos | 24 |
| eventos | 24 |
| muestras | 24 |
| covid-19 | 24 |
| comité | 24 |
| beneficio | 24 |
| asociado | 24 |
| acuerdo | 24 |
| Un | 24 |
| Qatar | 23 |
| Healthcare | 23 |
| Personal | 23 |
| Office | 23 |
| MRNA | 23 |
| M. | 23 |
| Long | 23 |
| Inflammatory | 23 |
| High | 23 |
| Heart | 23 |
| Gammacoronavirus | 23 |
| GS-5734 | 23 |
| Foundation | 23 |
| Evolution | 23 |
| E. | 23 |
| Design | 23 |
| Cyber | 23 |
| Ayurveda | 23 |
| Ang | 23 |
| Region | 23 |
| RaTG13 | 23 |
| Nature | 23 |
| Reuters | 23 |
| monocyte | 23 |
| Royal | 23 |
| veces | 23 |
| subgenomic | 23 |
| siendo | 23 |
| sich | 23 |
| renal | 23 |
| presencia | 23 |
| pp1a | 23 |
| muestra | 23 |
| protein | 23 |
| informado | 23 |
| establecer | 23 |
| anticuerpos | 23 |
| adversos | 23 |
| Virology | 23 |
| VTE | 23 |
| Synthesis | 23 |
| Support | 23 |
| general | 23 |
| SEIR | 23 |
| Para | 22 |
| Innate | 22 |
| LRT | 22 |
| Market | 22 |
| Murine | 22 |
| RECOMENDACIÓN | 22 |
| Patienten | 22 |
| Princess | 22 |
| R | 22 |
| Indian | 22 |
| Induction | 22 |
| Anti | 22 |
| HR2 | 22 |
| Fuerte | 22 |
| Fc | 22 |
| Dromedary | 22 |
| Domain | 22 |
| Diamond | 22 |
| Deltacoronavirus | 22 |
| Council | 22 |
| CCoV | 22 |
| Radiology | 22 |
| A59 | 22 |
| RSV | 22 |
| URT | 22 |
| SADS | 22 |
| ein | 22 |
| tratados | 22 |
| significativa | 22 |
| prueba | 22 |
| pp | 22 |
| par | 22 |
| nicht | 22 |
| marzo | 22 |
| Saif | 22 |
| estrategias | 22 |
| escala | 22 |
| hospitalizados | 22 |
| den | 22 |
| Unit | 22 |
| crítica | 22 |
| Surface | 22 |
| Technology | 22 |
| Transcription | 22 |
| Statement | 22 |
| Washington | 22 |
| adultos | 22 |
| aire | 22 |
| au | 22 |
| Crystal | 21 |
| OMS | 21 |
| Nipah | 21 |
| MPT | 21 |
| MAPK | 21 |
| IL-2 | 21 |
| HBV | 21 |
| 21 | |
| Period | 21 |
| necesidad | 21 |
| Crisis | 21 |
| Consensus | 21 |
| Cellular | 21 |
| Cardiac | 21 |
| CD26 | 21 |
| B. | 21 |
| A. | 21 |
| R0 | 21 |
| Pregnancy | 21 |
| χ2 | 21 |
| Recovery | 21 |
| medición | 21 |
| Southern | 21 |
| toma | 21 |
| sistema | 21 |
| respiratoires | 21 |
| requiere | 21 |
| reanimación | 21 |
| objetivo | 21 |
| siguientes | 21 |
| invasiva | 21 |
| east | 21 |
| disease | 21 |
| críticamente | 21 |
| carga | 21 |
| ante | 21 |
| inflammasome | 21 |
| RDV | 20 |
| NP | 20 |
| PE | 20 |
| PM | 20 |
| Peninsula | 20 |
| Women | 20 |
| Replicase | 20 |
| Systems | 20 |
| agudo | 20 |
| Investigation | 20 |
| Mpro | 20 |
| BAL | 20 |
| Interactions | 20 |
| Fusion | 20 |
| Evolutionary | 20 |
| Equipment | 20 |
| EMC | 20 |
| Camels | 20 |
| Binding | 20 |
| calidad | 20 |
| Arabian | 20 |
| 3b | 20 |
| alphacoronavirus | 20 |
| Tang | 20 |
| central | 20 |
| mejor | 20 |
| curso | 20 |
| κB | 20 |
| über | 20 |
| tasa | 20 |
| sedación | 20 |
| rutinaria | 20 |
| retrospectivo | 20 |
| pro | 20 |
| presenta | 20 |
| otras | 20 |
| residuos | 20 |
| kb | 20 |
| frecuencia | 20 |
| interferon | 20 |
| estado | 20 |
| evolución | 20 |
| fase | 20 |
| enfermos | 20 |
| función | 20 |
| gestión | 20 |
| grupos | 20 |
| Epidemiological | 19 |
| Sweden | 19 |
| Stability | 19 |
| Recognition | 19 |
| Pulmonary | 19 |
| Preparedness | 19 |
| Post | 19 |
| ORF6 | 19 |
| NF | 19 |
| Kock | 19 |
| H | 19 |
| GISAID | 19 |
| Agency | 19 |
| Endoplasmic | 19 |
| Darunavir | 19 |
| Creative | 19 |
| Commons | 19 |
| CoV-2-specific | 19 |
| COV | 19 |
| Broad | 19 |
| Austria | 19 |
| Approach | 19 |
| Americans | 19 |
| Xu | 19 |
| UN | 19 |
| factores | 19 |
| adecuado | 19 |
| enfermo | 19 |
| une | 19 |
| asociación | 19 |
| sind | 19 |
| rutina | 19 |
| ningún | 19 |
| muy | 19 |
| incluyendo | 19 |
| fuera | 19 |
| frente | 19 |
| final | 19 |
| evaluaron | 19 |
| manifestaciones | 19 |
| dificultad | 19 |
| cuanto | 19 |
| betacoronavirus | 19 |
| aún | 19 |
| camas | 19 |
| contexto | 19 |
| caso | 19 |
| demostrado | 19 |
| dentro | 19 |
| desenlaces | 19 |
| deterioro | 19 |
| L. | 18 |
| RAS | 18 |
| MRI | 18 |
| Nigeria | 18 |
| ORFs | 18 |
| Pakistan | 18 |
| Protective | 18 |
| SpO2 | 18 |
| Reticulum | 18 |
| Reverse | 18 |
| Seafood | 18 |
| Toronto | 18 |
| Surgeons | 18 |
| T. | 18 |
| Jeddah | 18 |
| Johnson | 18 |
| Campylobacter | 18 |
| Inhibitor | 18 |
| Decaro | 18 |
| Zhao | 18 |
| 3a | 18 |
| Abstract | 18 |
| August | 18 |
| Braithwaite | 18 |
| Central | 18 |
| EC50 | 18 |
| Infected | 18 |
| Economic | 18 |
| FCoV | 18 |
| Genetic | 18 |
| Greece | 18 |
| HR | 18 |
| Index | 18 |
| Type | 18 |
| proceso | 18 |
| cambios | 18 |
| reportaron | 18 |
| prevención | 18 |
| protocolo | 18 |
| protocolos | 18 |
| protéine | 18 |
| pruebas | 18 |
| replicase | 18 |
| requieren | 18 |
| perfusión | 18 |
| retiro | 18 |
| significativamente | 18 |
| sistemática | 18 |
| unidades | 18 |
| van | 18 |
| contagio | 18 |
| presentaron | 18 |
| todo | 18 |
| mouse | 18 |
| elementos | 18 |
| darunavir | 18 |
| middle | 18 |
| datos | 18 |
| doc_id | 18 |
| duración | 18 |
| edad | 18 |
| disponible | 18 |
| enfermedades | 18 |
| esto | 18 |
| están | 18 |
| genera | 18 |
| mid | 18 |
| est | 18 |
| hospitalización | 18 |
| John | 17 |
| GBS | 17 |
| Glycoprotein | 17 |
| IL-1 | 17 |
| Jan | 17 |
| Mechanism | 17 |
| K | 17 |
| Model | 17 |
| Moderna | 17 |
| Multisystem | 17 |
| Expression | 17 |
| Netherlands | 17 |
| FIG | 17 |
| CRP | 17 |
| Esta | 17 |
| Enzyme | 17 |
| Environmental | 17 |
| Egypt | 17 |
| Dengue | 17 |
| DIC | 17 |
| CEPI | 17 |
| BALB | 17 |
| Authorization | 17 |
| Arab | 17 |
| Age | 17 |
| < | 17 |
| QT | 17 |
| Position | 17 |
| adecuada | 17 |
| R. | 17 |
| después | 17 |
| términos | 17 |
| transmisión | 17 |
| seguimiento | 17 |
| riesgos | 17 |
| rCoVs | 17 |
| SBML | 17 |
| mediante | 17 |
| mRNAs | 17 |
| humano | 17 |
| ha | 17 |
| extubación | 17 |
| evaluación | 17 |
| procesos | 17 |
| dem | 17 |
| Zhejiang | 17 |
| daño | 17 |
| Situation | 17 |
| Test | 17 |
| Workers | 17 |
| Toll | 17 |
| Zheng | 17 |
| aunque | 17 |
| capacidad | 17 |
| cuadro | 17 |
| dass | 17 |
| PJT | 16 |
| KMHI | 16 |
| Kumar | 16 |
| London | 16 |
| Lu | 16 |
| Mexico | 16 |
| Non | 16 |
| Scopus | 16 |
| Papain | 16 |
| Pearson | 16 |
| Reviews | 16 |
| SARScoronavirus | 16 |
| SDO | 16 |
| Section | 16 |
| Hendra | 16 |
| Jordan | 16 |
| Summary | 16 |
| Guan | 16 |
| Gilead | 16 |
| Estimation | 16 |
| Emirates | 16 |
| Derrida | 16 |
| David | 16 |
| Critically | 16 |
| Contact | 16 |
| Climate | 16 |
| CRB-65 | 16 |
| CD147 | 16 |
| Breakthrough | 16 |
| Antigenicity | 16 |
| Allam | 16 |
| 8) | 16 |
| Stem | 16 |
| Corman | 16 |
| TBK1 | 16 |
| reducir | 16 |
| nelfinavir | 16 |
| parainfluenza | 16 |
| posterior | 16 |
| probabilidad | 16 |
| prono | 16 |
| | 16 |
| sars | 16 |
| implementación | 16 |
| trabajadores | 16 |
| tórax | 16 |
| unidad | 16 |
| valoración | 16 |
| wird | 16 |
| Tan | 16 |
| intervenciones | 16 |
| siempre | 16 |
| hyperimmune | 16 |
| comparado | 16 |
| herramienta | 16 |
| Vitro | 16 |
| Y. | 16 |
| aL | 16 |
| aus | 16 |
| cardiovasculares | 16 |
| alteraciones | 16 |
| complejidad | 16 |
| contaminación | 16 |
| da | 16 |
| ensayo | 16 |
| estancia | 16 |
| fecha | 16 |
| helicase | 16 |
| Nations | 15 |
| Neurosurgery | 15 |
| Neurological | 15 |
| Natural | 15 |
| Material | 15 |
| NTZ | 15 |
| Mice | 15 |
| Marburg | 15 |
| Nsp4 | 15 |
| Nsp1 | 15 |
| Signaling | 15 |
| ORF3a | 15 |
| ORF7a | 15 |
| P. | 15 |
| Paris | 15 |
| Pathogen | 15 |
| Regulation | 15 |
| Sarbecovirus | 15 |
| Survey | 15 |
| TLR | 15 |
| Literature | 15 |
| Lymphopenia | 15 |
| Colombia | 15 |
| Latin | 15 |
| LR | 15 |
| ABO | 15 |
| Blood | 15 |
| CO | 15 |
| CRS | 15 |
| Travel | 15 |
| Complement | 15 |
| DR | 15 |
| Death | 15 |
| Dong | 15 |
| Engineering | 15 |
| Esto | 15 |
| Frauen | 15 |
| Functional | 15 |
| GGO | 15 |
| Humoral | 15 |
| IL-1β | 15 |
| Immunity | 15 |
| Intelligence | 15 |
| Kim | 15 |
| Thoracic | 15 |
| Ro | 15 |
| Trials | 15 |
| leve | 15 |
| mayo | 15 |
| monitoreo | 15 |
| otro | 15 |
| población | 15 |
| polyprotein | 15 |
| presentan | 15 |
| primeras | 15 |
| primeros | 15 |
| realizaron | 15 |
| recurso | 15 |
| rendimiento | 15 |
| reportado | 15 |
| sanitario | 15 |
| situaciones | 15 |
| suficiente | 15 |
| tiempos | 15 |
| traqueostomía | 15 |
| virus | 15 |
| wie | 15 |
| ¼ | 15 |
| U | 15 |
| manos | 15 |
| útil | 15 |
| investigación | 15 |
| données | 15 |
| insuficiencia | 15 |
| VMNI | 15 |
| además | 15 |
| als | 15 |
| aplicación | 15 |
| asociados | 15 |
| bolsa | 15 |
| cardiovascular | 15 |
| deltacoronavirus | 15 |
| años | 15 |
| einen | 15 |
| expertos | 15 |
| inmunoglobulina | 15 |
| emitir | 15 |
| hacer | 15 |
| grave | 15 |
| inicial | 15 |
| específico | 15 |
| entrenamiento | 15 |
| Kinder | 14 |
| Northern | 14 |
| Koch | 14 |
| LDH | 14 |
| Letter | 14 |
| Life | 14 |
| MCP-1 | 14 |
| Merbecovirus | 14 |
| NIH | 14 |
| Nitazoxanide | 14 |
| Scientific | 14 |
| Paper | 14 |
| Park | 14 |
| Plan | 14 |
| Practice | 14 |
| Prediction | 14 |
| Publicado | 14 |
| RW | 14 |
| Recombination | 14 |
| SSE | 14 |
| Justice | 14 |
| Shanghai | 14 |
| Kerala | 14 |
| Epidemiologic | 14 |
| Intravenous | 14 |
| Cavanagh | 14 |
| Tabla | 14 |
| Action | 14 |
| Article | 14 |
| Assay | 14 |
| Based | 14 |
| Boris | 14 |
| C3 | 14 |
| CVD | 14 |
| Cao | 14 |
| Coronavirinae | 14 |
| Int | 14 |
| Dis | 14 |
| EUA | 14 |
| Estos | 14 |
| FiO2 | 14 |
| Flu | 14 |
| Hu | 14 |
| IFA | 14 |
| IP-10 | 14 |
| IVIG | 14 |
| Strategies | 14 |
| rápida | 14 |
| Verlauf | 14 |
| solución | 14 |
| médicos | 14 |
| múltiples | 14 |
| ni | 14 |
| nsp2 | 14 |
| nutrición | 14 |
| oseltamivir | 14 |
| personas | 14 |
| pulmonares | 14 |
| qui | 14 |
| temprana | 14 |
| metas | 14 |
| tracto | 14 |
| tratamientos | 14 |
| valores | 14 |
| ventilatorio | 14 |
| vez | 14 |
| virales | 14 |
| | | 14 |
| áreas | 14 |
| Vesicles | 14 |
| mostró | 14 |
| social | 14 |
| mental | 14 |
| directa | 14 |
| Wong | 14 |
| mayores | 14 |
| Young | 14 |
| Zealand | 14 |
| association | 14 |
| aumentar | 14 |
| biomarcadores | 14 |
| china | 14 |
| condición | 14 |
| corona | 14 |
| cardiaca | 14 |
| kann | 14 |
| disponibles | 14 |
| enfermería | 14 |
| equipos | 14 |
| específicos | 14 |
| existe | 14 |
| exposición | 14 |
| intensivista | 14 |
| mascarilla | 14 |
| Organ | 13 |
| Platform | 13 |
| Phosphorylation | 13 |
| PI3K | 13 |
| PA | 13 |
| Overview | 13 |
| NT | 13 |
| Nsp2 | 13 |
| Nsp16 | 13 |
| N. | 13 |
| Nrf2 | 13 |
| Preliminary | 13 |
| Police | 13 |
| Single | 13 |
| RTC | 13 |
| Registry | 13 |
| Renin | 13 |
| SARS‐CoV‐2 | 13 |
| SCoV | 13 |
| SL | 13 |
| SRAS | 13 |
| Services | 13 |
| Shenzhen | 13 |
| Species | 13 |
| Multicenter | 13 |
| Susceptibility | 13 |
| Multiple | 13 |
| Aljazeera | 13 |
| Mortality | 13 |
| Dexamethasone | 13 |
| Therapeutic | 13 |
| AIDS | 13 |
| Act | 13 |
| Akt | 13 |
| Artificial | 13 |
| Bangladesh | 13 |
| Biotechnology | 13 |
| Britain | 13 |
| COPD | 13 |
| California | 13 |
| ClinicalTrials.gov | 13 |
| Expert | 13 |
| MDA5 | 13 |
| FMSD | 13 |
| Growth | 13 |
| Guardian | 13 |
| Helicase | 13 |
| Il | 13 |
| Immunoglobulin | 13 |
| Joint | 13 |
| Jones | 13 |
| Kinase | 13 |
| Load | 13 |
| Lorusso | 13 |
| Target | 13 |
| Turkey | 13 |
| progresión | 13 |
| primera | 13 |
| incluidos | 13 |
| incluye | 13 |
| infectados | 13 |
| kcal | 13 |
| limitaciones | 13 |
| moderado | 13 |
| nombre | 13 |
| nuevo | 13 |
| paro | 13 |
| participantes | 13 |
| posibilidad | 13 |
| profesionales | 13 |
| heptad | 13 |
| protectora | 13 |
| quienes | 13 |
| respecto | 13 |
| respirador | 13 |
| saturación | 13 |
| series | 13 |
| sowie | 13 |
| terapéutico | 13 |
| vor | 13 |
| wurde | 13 |
| UTR | 13 |
| hospital | 13 |
| literatura | 13 |
| helvum | 13 |
| demostró | 13 |
| Upper | 13 |
| Vaccines | 13 |
| War | 13 |
| Working | 13 |
| abril | 13 |
| analysis | 13 |
| hay | 13 |
| bereits | 13 |
| características | 13 |
| citocinas | 13 |
| controles | 13 |
| cánula | 13 |
| basado | 13 |
| descrito | 13 |
| ello | 13 |
| fármacos | 13 |
| fiebre | 13 |
| esté | 13 |
| escalas | 13 |
| estar | 13 |
| disnea | 13 |
| disfunción | 13 |
| disease-2019 | 13 |
| detección | 13 |
| NendoU | 12 |
| Lee | 12 |
| NLRP3 | 12 |
| Masks | 12 |
| Manifestations | 12 |
| Major | 12 |
| MIS | 12 |
| Italia | 12 |
| Learning | 12 |
| Lai | 12 |
| JAK | 12 |
| Ivermectin | 12 |
| Initiative | 12 |
| Interventions | 12 |
| OPEC | 12 |
| Norway | 12 |
| Pangolin | 12 |
| OR | 12 |
| Regression | 12 |
| Immunodeficiency | 12 |
| Smart | 12 |
| Sepsis | 12 |
| Secretary | 12 |
| Schaller | 12 |
| Sars | 12 |
| RCT | 12 |
| Observational | 12 |
| Presymptomatic | 12 |
| Polyprotein | 12 |
| Parker | 12 |
| PRRs | 12 |
| PIP | 12 |
| PICU | 12 |
| Initial | 12 |
| Biology | 12 |
| IL-7 | 12 |
| BlueDot | 12 |
| Correlation | 12 |
| Comparison | 12 |
| Citation | 12 |
| Chief | 12 |
| CS | 12 |
| CA | 12 |
| Sun | 12 |
| Hopkins | 12 |
| BatCoV | 12 |
| BTK | 12 |
| Assembly | 12 |
| Antigen | 12 |
| Adult | 12 |
| Ad5-nCoV | 12 |
| Denmark | 12 |
| Dipeptidyl | 12 |
| ERK | 12 |
| Eastern | 12 |
| Energy | 12 |
| English | 12 |
| Este | 12 |
| ExoN | 12 |
| FFP3 | 12 |
| Factor | 12 |
| Fisher | 12 |
| Force | 12 |
| Forest | 12 |
| G. | 12 |
| Gao | 12 |
| GenBank | 12 |
| Heckert | 12 |
| Studien | 12 |
| Traditional | 12 |
| Surgery | 12 |
| nos | 12 |
| pour | 12 |
| positivo | 12 |
| pesar | 12 |
| pandemic | 12 |
| orotraqueal | 12 |
| nsps | 12 |
| negativos | 12 |
| qué | 12 |
| negativa | 12 |
| nAbs | 12 |
| multiorgan | 12 |
| medida | 12 |
| medicamento | 12 |
| marcadores | 12 |
| procedimientos | 12 |
| Surveillance | 12 |
| línea | 12 |
| tasas | 12 |
| ≥ | 12 |
| ≤ | 12 |
| técnicas | 12 |
| técnica | 12 |
| troponina | 12 |
| todas | 12 |
| supervivencia | 12 |
| relación | 12 |
| situación | 12 |
| signos | 12 |
| sein | 12 |
| sean | 12 |
| respiratorias | 12 |
| resolución | 12 |
| líquidos | 12 |
| realiza | 12 |
| leur | 12 |
| W. | 12 |
| capacitación | 12 |
| buffalo | 12 |
| betacoronaviruses | 12 |
| beneficios | 12 |
| aparición | 12 |
| alteración | 12 |
| Transplant | 12 |
| choque | 12 |
| Tourism | 12 |
| Thrombosis | 12 |
| Therapeutics | 12 |
| TS | 12 |
| interactome | 12 |
| Swine | 12 |
| catéter | 12 |
| Wei | 12 |
| cohorte | 12 |
| experiencia | 12 |
| institucional | 12 |
| iniciar | 12 |
| col | 12 |
| inflamación | 12 |
| hace | 12 |
| gravedad | 12 |
| forma | 12 |
| escenarios | 12 |
| ellos | 12 |
| documento | 12 |
| diferencias | 12 |
| definir | 12 |
| combinación | 12 |
| Milan | 11 |
| Malaysia | 11 |
| Monocyte | 11 |
| Microbiol | 11 |
| Michael | 11 |
| Medicina | 11 |
| Media | 11 |
| Maria | 11 |
| Intracellular | 11 |
| Literacy | 11 |
| Law | 11 |
| Kenya | 11 |
| Ju | 11 |
| Isothermal | 11 |
| Institutes | 11 |
| Insights | 11 |
| NICU | 11 |
| NEWS-2 | 11 |
| Sci | 11 |
| Nelfinavir | 11 |
| Neurologic | 11 |
| Imatinib | 11 |
| Serologic | 11 |
| Series | 11 |
| Sequences | 11 |
| Responses | 11 |
| Release | 11 |
| RBM | 11 |
| Quality | 11 |
| Primary | 11 |
| Portugal | 11 |
| Pharmacologic | 11 |
| Persons | 11 |
| Paradigm | 11 |
| PD-1 | 11 |
| ORF1ab | 11 |
| Neutrophil | 11 |
| Neuroticism | 11 |
| Infektion | 11 |
| Statistical | 11 |
| IL-4 | 11 |
| Belgium | 11 |
| Classification | 11 |
| Characterization | 11 |
| Chang | 11 |
| Ces | 11 |
| COVID‐19 | 11 |
| British | 11 |
| Biden | 11 |
| BCG | 11 |
| Cluster | 11 |
| Attribution | 11 |
| Assays | 11 |
| Alexander | 11 |
| Airway | 11 |
| AZ | 11 |
| AUC | 11 |
| ADAM17 | 11 |
| Clin | 11 |
| Como | 11 |
| ICTRP | 11 |
| Embecovirus | 11 |
| ICMR | 11 |
| Hajj | 11 |
| HMGB1 | 11 |
| HBPM | 11 |
| Graham | 11 |
| Fan | 11 |
| Emergence | 11 |
| ECDC | 11 |
| Countries | 11 |
| Dysregulation | 11 |
| Disulfiram | 11 |
| Disease-2019 | 11 |
| Deep | 11 |
| Das | 11 |
| Da | 11 |
| Cytokine | 11 |
| Specimens | 11 |
| HKU4 | 11 |
| Strain | 11 |
| gps | 11 |
| prona | 11 |
| presentación | 11 |
| posible | 11 |
| permite | 11 |
| patologías | 11 |
| patient | 11 |
| papel | 11 |
| multicéntrico | 11 |
| miocárdica | 11 |
| mejora | 11 |
| lugar | 11 |
| lograr | 11 |
| impacto | 11 |
| identificar | 11 |
| hidroxicloroquina | 11 |
| hemodinámica | 11 |
| hacia | 11 |
| puntos | 11 |
| recuperación | 11 |
| refractaria | 11 |
| tenían | 11 |
| Strategy | 11 |
| zum | 11 |
| ventilador | 11 |
| utilizados | 11 |
| tuvieron | 11 |
| transfusión | 11 |
| total | 11 |
| temprano | 11 |
| relacionadas | 11 |
| sobrevida | 11 |
| sistemas | 11 |
| siRNAs | 11 |
| será | 11 |
| segura | 11 |
| rápidamente | 11 |
| respiración | 11 |
| groupe | 11 |
| práctica | 11 |
| generales | 11 |
| années | 11 |
| altas | 11 |
| admisión | 11 |
| adicional | 11 |
| acceso | 11 |
| Zero | 11 |
| Yi | 11 |
| Vivo | 11 |
| VID-19 | 11 |
| Umifenovir | 11 |
| Ultrasound | 11 |
| Triage | 11 |
| Treatments | 11 |
| Transmembrane | 11 |
| Therapies | 11 |
| Tertiary | 11 |
| TLR7 | 11 |
| familia | 11 |
| anakinra | 11 |
| Welfare | 11 |
| anticoagulación | 11 |
| componentes | 11 |
| específica | 11 |
| eliminación | 11 |
| elevados | 11 |
| egreso | 11 |
| dispositivos | 11 |
| desarrollo | 11 |
| deberá | 11 |
| confirmado | 11 |
| esteroides | 11 |
| comorbilidades | 11 |
| centro | 11 |
| cardiaco | 11 |
| bioética | 11 |
| aux | 11 |
| aumenta | 11 |
| arritmias | 11 |
| Monitoring | 10 |
| Number | 10 |
| Nsp6 | 10 |
| Newborn | 10 |
| Neugeborenen | 10 |
| Nationwide | 10 |
| NTD | 10 |
| Multi | 10 |
| Monoclonal | 10 |
| MG | 10 |
| Mary | 10 |
| Madrid | 10 |
| Ma | 10 |
| One | 10 |
| MAbs | 10 |
| MAC | 10 |
| Localization | 10 |
| Kidney | 10 |
| Janus | 10 |
| ORF3 | 10 |
| Step | 10 |
| PHEV | 10 |
| PRS | 10 |
| IoT | 10 |
| Spring | 10 |
| Spanish | 10 |
| Shi | 10 |
| Sharing | 10 |
| Settings | 10 |
| Service | 10 |
| Reynolds | 10 |
| Res | 10 |
| Project | 10 |
| Procedural | 10 |
| Positive | 10 |
| Poland | 10 |
| Pipistrellus | 10 |
| Panel | 10 |
| PT | 10 |
| PSS | 10 |
| Jackson | 10 |
| 3c | 10 |
| Information | 10 |
| Deregt | 10 |
| DAD | 10 |
| Covid | 10 |
| Con | 10 |
| Cohort | 10 |
| CTL | 10 |
| COVID- | 10 |
| CO2 | 10 |
| BY | 10 |
| BALF | 10 |
| Avian | 10 |
| Autopsy | 10 |
| Amplification | 10 |
| Americas | 10 |
| Activities | 10 |
| Academy | 10 |
| ARIMA | 10 |
| Stroke | 10 |
| Deng | 10 |
| Disease-19 | 10 |
| Immunol | 10 |
| Education | 10 |
| Immunogenicity | 10 |
| ISUOG | 10 |
| IQR | 10 |
| Hasta | 10 |
| HEPA | 10 |
| Guillain | 10 |
| Griskevicius | 10 |
| Gong | 10 |
| Ghana | 10 |
| GCV | 10 |
| Finalmente | 10 |
| Fang | 10 |
| Failure | 10 |
| F. | 10 |
| Environ | 10 |
| Entre | 10 |
| Electronic | 10 |
| Storz | 10 |
| Pathogenicity | 10 |
| Suspected | 10 |
| necesarios | 10 |
| podrían | 10 |
| plan | 10 |
| peso | 10 |
| parámetros | 10 |
| paliativos | 10 |
| origen | 10 |
| noch | 10 |
| neurosurgery | 10 |
| monitoria | 10 |
| posteriores | 10 |
| modelos | 10 |
| marco | 10 |
| lactato | 10 |
| konnte | 10 |
| kappaB | 10 |
| jedoch | 10 |
| intervención | 10 |
| intensidad | 10 |
| posibles | 10 |
| predecir | 10 |
| incluso | 10 |
| secuelas | 10 |
| − | 10 |
| TC | 10 |
| óptimo | 10 |
| éticos | 10 |
| área | 10 |
| zur | 10 |
| wurden | 10 |
| soit | 10 |
| rhesus | 10 |
| preprint | 10 |
| responsable | 10 |
| respiratoire | 10 |
| respiradores | 10 |
| quien | 10 |
| puntaje | 10 |
| propone | 10 |
| primero | 10 |
| primer | 10 |
| inferior | 10 |
| profunda | 10 |
| incluir | 10 |
| cadáver | 10 |
| arterivirus | 10 |
| aquellos | 10 |
| alveolar | 10 |
| alguna | 10 |
| ajustar | 10 |
| aislamiento | 10 |
| adecuación | 10 |
| acerca | 10 |
| Zhu | 10 |
| X | 10 |
| Western | 10 |
| Vertical | 10 |
| V | 10 |
| Tx | 10 |
| identificación | 10 |
| Targets | 10 |
| TM | 10 |
| asoció | 10 |
| Zoonotic | 10 |
| comparación | 10 |
| dímero | 10 |
| hospitales | 10 |
| hubo | 10 |
| historia | 10 |
| consenso | 10 |
| guías | 10 |
| graves | 10 |
| gammacoronavirus | 10 |
| encuentra | 10 |
| encontraron | 10 |
| enzyme-2 | 10 |
| determinar | 10 |
| considera | 10 |
| desinfectante | 10 |
| dar | 10 |
| continuo | 10 |
| diferencia | 10 |
| células | 10 |
| ND | 9 |
| Lau | 9 |
| NS4B | 9 |
| Laboratories | 9 |
| Mechanical | 9 |
| Luo | 9 |
| Mesenchymal | 9 |
| Mission | 9 |
| NIPPV | 9 |
| Knowledge | 9 |
| LC3 | 9 |
| Inovio | 9 |
| Khan | 9 |
| Kaletra | 9 |
| Johns | 9 |
| Israel | 9 |
| Ireland | 9 |
| Iraq | 9 |
| Integrative | 9 |
| Initiation | 9 |
| Indonesia | 9 |
| Independent | 9 |
| OP | 9 |
| Implications | 9 |
| Illness | 9 |
| Networks | 9 |
| Restrictions | 9 |
| Oman | 9 |
| Options | 9 |
| Holy | 9 |
| Status | 9 |
| Screening | 9 |
| Schultze | 9 |
| School | 9 |
| SHERLOCK | 9 |
| Rousettus | 9 |
| Roles | 9 |
| Retrospective | 9 |
| Resource | 9 |
| Related | 9 |
| ROS | 9 |
| RAAS | 9 |
| Programme | 9 |
| Program | 9 |
| Profile | 9 |
| Professor | 9 |
| Politics | 9 |
| Pathways | 9 |
| PUI | 9 |
| PP | 9 |
| PIMS | 9 |
| PAFI | 9 |
| Other | 9 |
| Orthocoronavirinae | 9 |
| IVIg | 9 |
| Basis | 9 |
| Haraway | 9 |
| Cheng | 9 |
| CPT | 9 |
| COVID-19-infected | 9 |
| CNN | 9 |
| CMs | 9 |
| CD16 | 9 |
| CCL2 | 9 |
| Business | 9 |
| Briefing | 9 |
| Brain | 9 |
| Biological | 9 |
| BCX4430 | 9 |
| AutoDock | 9 |
| Aunque | 9 |
| Attack | 9 |
| Area | 9 |
| Allergy | 9 |
| Against | 9 |
| African | 9 |
| Accessory | 9 |
| Access | 9 |
| Accepted | 9 |
| AP | 9 |
| AAK1 | 9 |
| -drug | 9 |
| Super | 9 |
| Challenge | 9 |
| Cleavage | 9 |
| Guideline | 9 |
| Common | 9 |
| GfCoV | 9 |
| Genetics | 9 |
| Future | 9 |
| Funding | 9 |
| Front | 9 |
| Fluid | 9 |
| Flights | 9 |
| Finland | 9 |
| Ethics | 9 |
| Emerg | 9 |
| EP | 9 |
| ENT | 9 |
| ED | 9 |
| ECoV | 9 |
| Du | 9 |
| Distribution | 9 |
| Differential | 9 |
| Diagnostic | 9 |
| Delphi | 9 |
| DE | 9 |
| Cruise | 9 |
| Coronavirus-2 | 9 |
| Conscientiousness | 9 |
| Congo | 9 |
| Complications | 9 |
| Stress | 9 |
| espacio | 9 |
| TFV | 9 |
| publicación | 9 |
| procalcitonina | 9 |
| principalmente | 9 |
| principales | 9 |
| previamente | 9 |
| presentar | 9 |
| predictores | 9 |
| positivos | 9 |
| plusieurs | 9 |
| patología | 9 |
| ofrecer | 9 |
| observacional | 9 |
| nur | 9 |
| nsp14 | 9 |
| neurológicas | 9 |
| nervioso | 9 |
| necesaria | 9 |
| nacional | 9 |
| mostraron | 9 |
| moral | 9 |
| monitorización | 9 |
| mmHg | 9 |
| membrana | 9 |
| mejorar | 9 |
| medio | 9 |
| medicina | 9 |
| proteína | 9 |
| qSOFA | 9 |
| liberación | 9 |
| rCoV | 9 |
| TGE | 9 |
| último | 9 |
| índices | 9 |
| ésta | 9 |
| vital | 9 |
| trombosis | 9 |
| tres | 9 |
| tormenta | 9 |
| tomografía | 9 |
| terapéutica | 9 |
| tenía | 9 |
| temperatura | 9 |
| telesalud | 9 |
| tPA | 9 |
| sugieren | 9 |
| spermidine | 9 |
| sintomatología | 9 |
| significativo | 9 |
| siRNA | 9 |
| segunda | 9 |
| sangre | 9 |
| resistencia | 9 |
| reportados | 9 |
| receptor | 9 |
| razonable | 9 |
| mL | 9 |
| st | 9 |
| l'épidémie | 9 |
| continua | 9 |
| compararon | 9 |
| claro | 9 |
| citoquinas | 9 |
| cambio | 9 |
| brote | 9 |
| bloqueo | 9 |
| bien | 9 |
| author(s | 9 |
| ausencia | 9 |
| asistencial | 9 |
| animal | 9 |
| alerta | 9 |
| administración | 9 |
| aber | 9 |
| Year | 9 |
| Yan | 9 |
| X. | 9 |
| Ventilation | 9 |
| Vector | 9 |
| Vascular | 9 |
| Van | 9 |
| UAE | 9 |
| Threat | 9 |
| interleukin-6 | 9 |
| Targeting | 9 |
| comunidad | 9 |
| Version | 9 |
| controlado | 9 |
| estas | 9 |
| incremento | 9 |
| individuos | 9 |
| cuidado | 9 |
| incidencia | 9 |
| implementar | 9 |
| huésped | 9 |
| grado | 9 |
| gasto | 9 |
| frecuente | 9 |
| formación | 9 |
| fenotipos | 9 |
| estén | 9 |
| génome | 9 |
| espontánea | 9 |
| difícil | 9 |
| especificidad | 9 |
| definida | 9 |
| dados | 9 |
| dexametasona | 9 |
| diese | 9 |
| efectiva | 9 |
| efectividad | 9 |
| eficacia | 9 |
| desinfección | 9 |
| Mobility | 8 |
| Nervous | 8 |
| Methyltransferase | 8 |
| Modeling | 8 |
| NCP | 8 |
| Merkel | 8 |
| NTE | 8 |
| Narrative | 8 |
| Nsp12 | 8 |
| Neural | 8 |
| News | 8 |
| Nsp14 | 8 |
| Nsp3 | 8 |
| Nsp9 | 8 |
| Nucleotide | 8 |
| Mebus | 8 |
| OIE | 8 |
| ORF5 | 8 |
| Mediterranean | 8 |
| Lack | 8 |
| Manejo | 8 |
| Kenrick | 8 |
| Importation | 8 |
| Oil | 8 |
| Inc. | 8 |
| Interleukin-6 | 8 |
| Islands | 8 |
| Italian | 8 |
| JAMA | 8 |
| K. | 8 |
| Lebanon | 8 |
| Maharashtra | 8 |
| Leung | 8 |
| Level | 8 |
| Like | 8 |
| Lin | 8 |
| MCP1 | 8 |
| MD | 8 |
| MLT | 8 |
| MVA | 8 |
| Obstetricians | 8 |
| Random | 8 |
| Olympics | 8 |
| Quantitative | 8 |
| RNase | 8 |
| RTV | 8 |
| Regulatory | 8 |
| Relation | 8 |
| Resilience | 8 |
| Role | 8 |
| Rome | 8 |
| SAR | 8 |
| SARSr | 8 |
| SVM | 8 |
| SW1 | 8 |
| Sanità | 8 |
| Schwangeren | 8 |
| Sequence | 8 |
| Ship | 8 |
| Singh | 8 |
| IRF7 | 8 |
| Quarantine | 8 |
| Protocol | 8 |
| Online | 8 |
| Products | 8 |
| Organisation | 8 |
| Oseltamivir | 8 |
| PUIs | 8 |
| Paguma | 8 |
| Panic | 8 |
| Perspective | 8 |
| Point | 8 |
| Policy | 8 |
| Population | 8 |
| Porcine | 8 |
| Pradesh | 8 |
| Presence | 8 |
| Presentation | 8 |
| Press | 8 |
| Prevalence | 8 |
| Primer | 8 |
| Production | 8 |
| Immunology | 8 |
| Chile | 8 |
| IL | 8 |
| CAM | 8 |
| CP | 8 |
| CRRT | 8 |
| Cap | 8 |
| Cas13 | 8 |
| Cette | 8 |
| Chain | 8 |
| Cinanserin | 8 |
| Cities | 8 |
| Clade | 8 |
| Co | 8 |
| CoV-2/ | 8 |
| Cochrane | 8 |
| Comorbidities | 8 |
| Contamination | 8 |
| Controlled | 8 |
| Core | 8 |
| Corticosteroid | 8 |
| CORONAVIRUS | 8 |
| Burden | 8 |
| Course | 8 |
| Brian | 8 |
| Song | 8 |
| 229E | 8 |
| ACV | 8 |
| AKT | 8 |
| Además | 8 |
| Ag | 8 |
| Aldosterone | 8 |
| Apoptosis | 8 |
| Apple | 8 |
| Applied | 8 |
| Asymptomatic | 8 |
| Aven | 8 |
| BBB | 8 |
| Barré | 8 |
| Bats | 8 |
| Bibliometric | 8 |
| Blakey | 8 |
| County | 8 |
| Cov | 8 |
| IFNs | 8 |
| Environment | 8 |
| Express | 8 |
| Extraversion | 8 |
| Fast | 8 |
| Feb | 8 |
| Festival | 8 |
| Fight | 8 |
| Ge | 8 |
| Genes | 8 |
| Geographic | 8 |
| Gorbalenya | 8 |
| Great | 8 |
| H. | 8 |
| HA | 8 |
| Heme | 8 |
| Hemida | 8 |
| Home | 8 |
| Household | 8 |
| Exoribonuclease | 8 |
| Enhancement | 8 |
| Crouch | 8 |
| Eine | 8 |
| Cuba | 8 |
| Cup | 8 |
| Cytoplasmic | 8 |
| Czech | 8 |
| Daniel | 8 |
| Database | 8 |
| Defense | 8 |
| Democracy | 8 |
| Diao | 8 |
| Document | 8 |
| Dose | 8 |
| Double | 8 |
| Dr | 8 |
| Drugs | 8 |
| E2 | 8 |
| Earth | 8 |
| Economy | 8 |
| Smith | 8 |
| Springer | 8 |
| oxygenase-1 | 8 |
| limpieza | 8 |
| material | 8 |
| mecanismos | 8 |
| medir | 8 |
| mesylate | 8 |
| modalidades | 8 |
| moderada | 8 |
| muerte | 8 |
| muestran | 8 |
| mínimo | 8 |
| nd | 8 |
| negativas | 8 |
| nidovirus | 8 |
| notamment | 8 |
| novo | 8 |
| nsp4 | 8 |
| nítrico | 8 |
| objetivos | 8 |
| lung | 8 |
| laboratorio | 8 |
| optimizar | 8 |
| keine | 8 |
| global | 8 |
| griffithsin | 8 |
| haya | 8 |
| hemodinámico | 8 |
| igual | 8 |
| il | 8 |
| incluyeron | 8 |
| indirecta | 8 |
| inflamatorios | 8 |
| ingresados | 8 |
| iniciales | 8 |
| institucionales | 8 |
| intensivistas | 8 |
| interferón | 8 |
| intravenosa | 8 |
| isquémico | 8 |
| kDa | 8 |
| obtener | 8 |
| orgánica | 8 |
| für | 8 |
| sospechoso | 8 |
| superior | 8 |
| symptomatologie | 8 |
| sólo | 8 |
| terapias | 8 |
| tolerancia | 8 |
| trans | 8 |
| turkey | 8 |
| utilidad | 8 |
| utilizado | 8 |
| variabilidad | 8 |
| vasculares | 8 |
| ventilados | 8 |
| ética | 8 |
| índice | 8 |
| óxido | 8 |
| β1b | 8 |
| Standard | 8 |
| superficies | 8 |
| sobrevivientes | 8 |
| paso | 8 |
| sobrecarga | 8 |
| preoxigenación | 8 |
| prevenir | 8 |
| primario | 8 |
| pronación | 8 |
| proporción | 8 |
| publicaciones | 8 |
| publicado | 8 |
| puedan | 8 |
| pulmón | 8 |
| quirúrgica | 8 |
| realizarse | 8 |
| reciente | 8 |
| replicación | 8 |
| respectivamente | 8 |
| seq | 8 |
| serie | 8 |
| siguiendo | 8 |
| garantizar | 8 |
| limitada | 8 |
| frecuentes | 8 |
| anterior | 8 |
| Wan | 8 |
| Wit | 8 |
| Ye | 8 |
| adecuadamente | 8 |
| agentes | 8 |
| ageusia | 8 |
| agua | 8 |
| alfa | 8 |
| antimaláricos | 8 |
| capilar | 8 |
| aspectos | 8 |
| azitromicina | 8 |
| baicalin | 8 |
| bajos | 8 |
| beta-1b | 8 |
| bioseguridad | 8 |
| bis | 8 |
| bluecomb | 8 |
| formes | 8 |
| Vautherot | 8 |
| VLP | 8 |
| Urban | 8 |
| Strand | 8 |
| Síndrome | 8 |
| Task | 8 |
| Taylor | 8 |
| Temporal | 8 |
| Tenofovir | 8 |
| Texas | 8 |
| Third | 8 |
| Thrombocytopenia | 8 |
| Tissue | 8 |
| Tomography | 8 |
| Transport | 8 |
| Troponin | 8 |
| UPF1 | 8 |
| Uganda | 8 |
| Une | 8 |
| Unique | 8 |
| broncoscopia | 8 |
| Viren | 8 |
| causas | 8 |
| diciembre | 8 |
| disposición | 8 |
| documentado | 8 |
| dolor | 8 |
| détection | 8 |
| eficiencia | 8 |
| encefalitis | 8 |
| enero | 8 |
| espectro | 8 |
| específicas | 8 |
| espèces | 8 |
| essentiellement | 8 |
| estructura | 8 |
| estrés | 8 |
| evitando | 8 |
| examen | 8 |
| falta | 8 |
| fases | 8 |
| disminuye | 8 |
| especiales | 8 |
| cobicistat | 8 |
| contacto | 8 |
| diagnóstica | 8 |
| ce | 8 |
| centros | 8 |
| cerebral | 8 |
| cette | 8 |
| coV-2 | 8 |
| colaboradores | 8 |
| confirmados | 8 |
| contact | 8 |
| contar | 8 |
| correlación | 8 |
| corticoides | 8 |
| cyclophilin | 8 |
| demanda | 8 |
| derechos | 8 |
| describieron | 8 |
| Mutation | 7 |